RecruitingPreeclampsiaGestational HypertensionHypertensive Disorder of Pregnancy
The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.
Eligible age
14–49 yrs
Accepts
Women
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.
Sponsor: University of Alabama at Birmingham
You may qualify if…
- ✓ Pregnant women
- ✓ Gestational age: 23 weeks, 0 days to 35 weeks, 6 days
- ✓ Hypertensive disorder of pregnancy including gestational hypertension or preeclampsia, the non-severe form at enrollment, which is called without severe features by the American College of Obstetricians and Gynecologists.
- ✓ No evidence of the severe form of preeclampsia, termed severe features, as outlined in maternal exclusions
- ✓ No indication for delivery at the time of enrollment.
- ✓ Planned expectant management at time of enrollment
- ✓ Singleton or dichorionic twin gestation, defined at and beyond 14 weeks gestation. (A pregnancy complicated by a vanishing twin in the first trimester defined as less than 14 weeks gestation will be eligible.)
- ✓ Intact membranes
You may not qualify if…
- ✕ Preeclampsia with severe features, defined per ACOG as:
- ✕ Systolic blood pressure of 160 mm Hg or more, or diastolic blood pressure of 110 mm Hg or more on two occasions at least 4 hours apart (unless antihypertensive therapy is initiated before this time)
- ✕ Thrombocytopenia defined as: lower than 100 x 10e9 platelets/L
- ✕ Impaired liver function that is not accounted for by alternative diagnoses and as indicated by abnormally elevated blood concentrations of liver enzymes (to more than twice the upper limit normal concentrations), or by severe persistent right upper quadrant or epigastric pain unresponsive to medications
- ✕ Renal insufficiency (serum creatinine concentration more than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease)
- ✕ Pulmonary edema
- ✕ New-onset headache unresponsive to medication and not accounted for by alternative diagnoses
- ✕ Visual disturbances
Where it's recruiting
Source: ClinicalTrials.gov · NCT05676476 · last updated 2025-12-12